Reference based sensitivity analysis for clinical trials with missing data via multiple imputation Suzie Cro 1,2, Mike Kenward 2, James Carpenter 1,2 1.

Slides:



Advertisements
Similar presentations
Handling attrition and non- response in longitudinal data Harvey Goldstein University of Bristol.
Advertisements

Non response and missing data in longitudinal surveys.
Phase II/III Design: Case Study
Study Size Planning for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Handling (and Preventing) Missing Data in RCTs ASENT March 7, 2009 Janet Wittes Statistics Collaborative.
Designing Clinical Research Studies An overview S.F. O’Brien.
1 QOL in oncology clinical trials: Now that we have the data what do we do?
Simulation of “forwards-backwards” multiple imputation technique in a longitudinal, clinical dataset Catherine Welch 1, Irene Petersen 1, James Carpenter.
Systematic Review of Literature Part XIX Analyzing and Presenting Results.
CCEB Modeling Quality of Life Data with Missing Values Andrea B. Troxel, Sc.D. Assistant Professor of Biostatistics Center for Clinical Epidemiology and.
Efficient modelling of record linked data A missing data perspective Harvey Goldstein Record Linkage Methodology Research Group Institute of Child Health.
Session 4: Analysis and reporting Managing missing data Rob Coe (CEM, Durham) Developing a statistical analysis plan Hannah Buckley (York Trials Unit)
To change this title, go to Notes Master
Missing Data and Repeated Measurements
An Experimental Paradigm for Developing Dynamic Treatment Regimes S.A. Murphy Univ. of Michigan March, 2004.
An Experimental Paradigm for Developing Adaptive Treatment Strategies S.A. Murphy Univ. of Michigan UNC: November, 2003.
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
An Experimental Paradigm for Developing Adaptive Treatment Strategies S.A. Murphy Univ. of Michigan February, 2004.
Raymond J. Carroll Texas A&M University LOCF and MMRM: Thoughts on Comparisons.
Sample Size Annie Herbert Medical Statistician Research & Development Support Unit Salford Royal Hospitals NHS Foundation Trust
Statistical Methods for Missing Data Roberta Harnett MAR 550 October 30, 2007.
Biost 511 DL Discussion Section Announcements Quiz 1 (CEU students only) Will be available on Canvas.uw.edu Friday 12 pm – Sunday 11:59 pm One hour to.
Advanced Statistics for Interventional Cardiologists.
The Mimix Command Reference Based Multiple Imputation For Sensitivity Analysis of Longitudinal Trials with Protocol Deviation Suzie Cro EMERGE.
Workshop on methods for studying cancer patient survival with application in Stata Karolinska Institute, 6 th September 2007 Modeling relative survival.
Guide to Handling Missing Information Contacting researchers Algebraic recalculations, conversions and approximations Imputation method (substituting missing.
MISSING DATA DSBS Meeting 28 May 2009 Kristian Windfeld, Genmab.
1 ICEBOH Split-mouth studies and systematic reviews Ian Needleman 1 & Helen Worthington 2 1 Unit of Periodontology UCL Eastman Dental Institute International.
1 Multiple Imputation : Handling Interactions Michael Spratt.
Biostatistics Case Studies 2007 Peter D. Christenson Biostatistician Session 3: Incomplete Data in Longitudinal Studies.
Consumer behavior studies1 CONSUMER BEHAVIOR STUDIES STATISTICAL ISSUES Ralph B. D’Agostino, Sr. Boston University Harvard Clinical Research Institute.
Biostatistics Case Studies 2008 Peter D. Christenson Biostatistician Session 5: Choices for Longitudinal Data Analysis.
Name:Shanil Ebrahim, MSc, MSc, PhD Departments of Clinical Epidemiology & Biostatistics, and Anesthesia McMaster University, Hamilton, Canada Stanford.
1 Updates on Regulatory Requirements for Missing Data Ferran Torres, MD, PhD Hospital Clinic Barcelona Universitat Autònoma de Barcelona.
© John M. Abowd 2007, all rights reserved General Methods for Missing Data John M. Abowd March 2007.
1 G Lect 13W Imputation (data augmentation) of missing data Multiple imputation Examples G Multiple Regression Week 13 (Wednesday)
Missing Values Raymond Kim Pink Preechavanichwong Andrew Wendel October 27, 2015.
A REVIEW By Chi-Ming Kam Surajit Ray April 23, 2001 April 23, 2001.
Simulation Study for Longitudinal Data with Nonignorable Missing Data Rong Liu, PhD Candidate Dr. Ramakrishnan, Advisor Department of Biostatistics Virginia.
Motivation Using SMART research designs to improve individualized treatments Alena Scott 1, Janet Levy 3, and Susan Murphy 1,2 Institute for Social Research.
1 Handling of Missing Data. A regulatory view Ferran Torres, MD, PhD IDIBAPS. Hospital Clinic Barcelona Autonomous University of Barcelona (UAB)
A shared random effects transition model for longitudinal count data with informative missingness Jinhui Li Joint work with Yingnian Wu, Xiaowei Yang.
Biostatistics Case Studies Peter D. Christenson Biostatistician Session 3: Missing Data in Longitudinal Studies.
Reference based multiple imputation;
A systematic review of selected journals
From: Montelukast, a Leukotriene Receptor Antagonist, in Combination With Loratadine, a Histamine Receptor Antagonist, in the Treatment of Chronic Asthma.
MISSING DATA AND DROPOUT
The Centre for Longitudinal Studies Missing Data Strategy
Sample Size Estimation
Strategies to incorporate pharmacoeconomics into pharmacotherapy
Sensitivity analyses for missing not at random outcomes in clinical trials (Invited Session 1.2: Recent Advances in Methods for Handling Missing Data in.
Re-randomising patients within clinical trials
Multiple Imputation Using Stata
How to handle missing data values
Analyzing Intervention Studies
Filming: 15th of Febuary 2016, London, UK
Aligning Estimands and Estimators – A Case Study Sept 13, 2018 Elena Polverejan Vladimir Dragalin Quantitative Sciences Janssen R&D, Johnson & Johnson.
Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:
Mark Rothmann U.S. Food and Drug Administration September 14, 2018
Common Problems in Writing Statistical Plan of Clinical Trial Protocol
Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.
Non response and missing data in longitudinal surveys
A methodological assessment of diurnal variability of peak flow as a basis for comparing different inhaled steroid formulations  John H. Toogood, MD,
What Do We Know About Estimators for the Treatment Policy Estimand
Handling Missing Not at Random Data for Safety Endpoint in the Multiple Dose Titration Clinical Pharmacology Trial Li Fan*, Tian Zhao, Patrick Larson Merck.
Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma  William.
Percent of patients with ASDAS inactive disease grouped by normal or elevated CRP at baseline through week 156. §p
Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.
Considerations for the use of multiple imputation in a noninferiority trial setting Kimberly Walters, Jie Zhou, Janet Wittes, Lisa Weissfeld Joint Statistical.
How Should We Select and Define Trial Estimands
Presentation transcript:

Reference based sensitivity analysis for clinical trials with missing data via multiple imputation Suzie Cro 1,2, Mike Kenward 2, James Carpenter 1,2 1 MRC Clinical Trials Unit at UCL 2 The London School of Hygiene and Tropical Medicine

Outline Reference based multiple imputation; asthma trial Motivation for evaluation Information anchoring principle Investigation of Rubin’s multiple imputation variance estimator Conclusions

Example – asthma trial Placebo vs. Budesonide for patients with chronic asthma Forced Expiratory Volume in 1 second (FEV 1 ) recorded at baseline, 2, 4, 8 and 12 weeks Primary outcome: mean treatment group difference at 12 weeks Only 37/90 Placebo and 71/90 Budesonide completed Busse et al. (1998)

Example – asthma trial Any analysis must make an untestable assumption about the unobserved data Wrong assumption  biased treatment estimate Primary analysis – Missing-at-Random (MAR) A set of analyses where the missing data is handled in different ways as compared to the primary analysis should be undertaken

Example – asthma trial - MAR Placebo MAR means Active MAR means Time (weeks)

Example – asthma trial - MAR Observed FEV 1 Placebo MAR means Active MAR means Time (weeks)

Example – asthma trial - MAR Observed FEV 1 Placebo MAR means Active MAR means Time (weeks)

Example – asthma trial - MAR Imputed FEV 1 Observed FEV 1 Placebo MAR means Active MAR means Time (weeks)

Example – asthma trial – Jump to reference Imputed FEV 1 Observed FEV 1 Placebo MAR means Active MAR means Time (weeks)

Reference based sensitivity analysis ‘Fill in’ the missing data under reference based assumption multiple times Analyse each imputed data set using the primary design based analysis model Get one overall treatment effect and estimate of variance using Rubin’s rules Carpenter, Roger and Kenward (2013)

Reference based sensitivity analysis ‘Fill in’ the missing data under reference based assumption multiple times Analyse each imputed data set using the primary design based analysis model Get one overall treatment effect and estimate of variance using Rubin’s rules Carpenter, Roger and Kenward (2013)

Motivation for evaluation Rubin's variance formula requires the imputation and analysis models to be congenial - the imputation and analysis model must have the same content and structure Here the analysis model makes different assumptions to the imputation model, violating the usual justification!

Motivation for evaluation 1.What properties do we require of our variance estimate in the reference based sensitivity analysis setting? 2.Does Rubin’s variance estimator provide an appropriate estimate of variance?

Information anchoring A loss of information is inevitable with missing data The extent of information loss in primary analysis (MAR) is intrinsically linked to the analysis model A natural principle for the treatment estimator variance is to keep the information loss due to missing data constant or anchored across primary and all sensitivity analysis Sensitivity analyses should not inject information ‘by the back door’

Information anchoring Variance estimate Full data; no deviations occur Full data; deviation data follow the specific reference assumption Deviation data are missing and multiply imputed - MAR For the design based analysis model let,

Information anchoring Variance estimate Full data; no deviations occur Full data; deviation data follow the specific reference assumption Deviation data are missing and multiply imputed - MAR For the design based analysis model let,

Information anchoring Variance estimate Full data; no deviations occur Full data; deviation data follow the specific reference assumption Deviation data are missing; analysis under MAR For the design based analysis model let,

Information anchoring Variance estimate Full data; no deviations occur Full data; deviation data follow the specific reference assumption Deviation data are missing; analysis under MAR For the design based analysis model let,

Information anchoring Variance estimate Full data; no deviations occur Full data; deviation data follow the specific reference assumption Deviation data are missing; analysis under MAR For the design based analysis model let,

Rubin’s variance estimate Proposition: In all settings where,

Rubin’s variance estimate

Software Mimix implements the reference based MI procedures in Stata Download in Stata using ssc install mimix SAS Macro’s available at

Conclusions The loss of information due to missing data across primary and design based sensitivity analysis should be constant Rubin’s variance estimate anchors the loss of information in the primary analysis to a very good approximation

Conclusions The loss of information due to missing data across primary and design based sensitivity analysis should be constant Rubin’s variance estimate anchors the loss of information in the primary analysis to a very good approximation Rubin’s rules provide an appropriate estimate of variance when using reference based multiple imputation for sensitivity analysis

Carpenter JR, Roger JH, Kenward MG, Analysis of Longitudinal Trials with protocol deviation: a framework for relevant accessible assumptions and inference via multiple imputation, Journal of Biopharmaceutical Statistics, 23: , Carpenter JR, Roger JH, Cro S, Kenward MG, Response to comments by Seaman et al. on ‘Analysis of Longitudinal Trials with protocol deviation: a framework for relevant accessible assumptions and inference via multiple imputation’, Journal of Biopharmaceutical Statistics, 24: , Cro S, Morris TP, Kenward MG, Carpenter JR, Reference-based sensitivity analysis via multiple imputation for longitudinal trials with protocol deviation, Stata Journal, 16:2: , Rubin DB, Multiple imputation for nonresponse in surveys, Wiley series in probability and mathematical statistics, USA: John Wiley & Sons, 1987.